Kornimate/medical-research-clean huggingface dataset:
osi-774 (erlotinib, tarceva) in elderly patients

Conditions: Non-Small Cell Lung Cancer

Summary: the purpose of this research study is to determine if osi-774 (tarceva) is effective in the treatment of non-small cell lung cancer and to further study its side effects. the investigators would also like to estimate disease-related symptom improvement rates using a questionnaire.

in recent years, it has been shown that the degree of improvement achievable with chemotherapy has plateaued with the use of chemotherapy doublets. the presence of co-morbid conditions and poor performance status may preclude the use of chemotherapy in many elderly patients, which even in the medically fit, has modest benefits. the advent of targeted cancer therapy with the discovery of tyrosine kinases as mediators of tumor growth, with its limited toxicity profile, offers a promising approach to the treatment of nsclc, in particular to the elderly subset of patients. the encouraging results from the other trials provide a strong rationale to evaluate an oral egfr-tyrosine kinase inhibitor osi-774 in patients with advanced and inoperable nsclc over the age of 70. in vitro and clinical data suggest a dose- dependent response with tarceva (genentech, data on file).

Eligibility criteria:
inclusion criteria: * patients must have confirmed non-small cell lung cancer. age \> 65 years patients must have adequate organ and marrow function exclusion criteria: * patients who have had prior chemotherapy will be excluded. patients may not be receiving any other investigational agents.
superiority of vcd versus ctd in patients with newly diagnose multiple myeloma eligible for transplantation

Conditions: Multiple Myeloma; Effects of Chemotherapy

Summary: this study compared two main different induction protocols used to treat myeloma eligible patients in brazil. vcd against ctd.

the primary aim was observe response rate after 4 induction cycles.

Eligibility criteria:
inclusion criteria: * multiple myeloma newly diagnose elegible to autologous transplantation patients submitted to ctd or vcd myeloma patients newly diagnose \>18yo exclusion criteria: * other chemotherapy induction protocol
determining predictors of restenosis in femoropopliteal lesions

Conditions: Peripheral Vascular Disease

Summary: a prospective, single-center, real-world study on intravascular ultrasound measurements after percutaneous transluminal angioplasty and stenting in the treatment of femoropopliteal lesions.

intravascular ultrasound is considered important tool in endovascular procedures of coronary territory. information such as vessel diameter, stent expansion, residual stenosis, helped in better understanding of the disease, treatment and stent behavior. however, as a different anatomical territory with major hemodynamic differences, many of these concepts could not be reproduced in the femoropopliteal segment. the purpose of this study is to correlate data collected by intraoperative intravascular ultrasound after the angioplasty procedure with stent placement in femoropopliteal arterial lesions and patency of this revascularization within 12 months.

Eligibility criteria:
inclusion criteria: * stenotic (\>50%) or occlusive atherosclerotic disease of the femoropopliteal arteries; * successful lesion passage passed with conventional mechanical guidewires; * symptomatic critical limb ischemia (rutherford 4, 5, 6); * life-expectancy of more than 12 months; * tha patient must be willing and able to return to the appropriate follow-up times for the duration of the study; * te patient must provide written patient informed consent that is approved by the ethics committee. exclusion criteria: * patient refusing treatment; * the reference segment diameter is not suitable fo available balloon and/or stent design; * unsuccessfully treated (\>30% residual stenosis) proximal inflow limiting arterial stenosis; * previously implanted stent(s) or percutaneous transluminal angioplasty at the same lesion site; * the patient has a known allergy to heparin, aspirin or other anticoagulant/antiplatelet therapies or a bleeding diatheses or is unable, or unwilling, to tolerate such therapies; * the patent has a history of prior life-threatening contrast media reaction; * the patient is currently enrolled in another investigational device or drug trial; * the patient is currently breast-feeding, pregnant or intends to become pregnant; * the patient is mentally ill or retarded.
efficacy of non-invasive nesa neuromodulation in fibromyalgia

Conditions: Fibromyalgia

Summary: fibromyalgia is a chronic condition that causes pain throughout the body, fatigue and other symptoms. among the most common clinical symptoms are sleep and anxiety disorders. all these symptoms are very disabling and have a negative impact on the quality of life of these people. there is currently no curative treatment for this pathology and current treatments focus their efforts on reducing the intensity of the symptoms. the current approach is mainly pharmacological, with the possible side effects that this entails.

the nesa xsignal® device is a non-invasive, low-frequency neuromodulation device that uses microcurrents to restore the electrical balance in the body. this technology is approved as medical equipment and is ce marked (attached in separate files). this non-invasive neuromodulation equipment is beginning to show promising results in patients with sleep disorders. so it can be a useful tool to reduce the impact on the quality of life of people with fibromyalgia.

Eligibility criteria:
inclusion criteria: * patients over 18 years of age * diagnosis of fibromyalgia meeting acr 1990/20101,2 criteria, made by a physician, documented by a clinical report. * diagnosis of fibromyalgia made at least 12 months ago * stable baseline treatment in the month prior to inclusion in the study * signed informed consent * in normal condition and mentally competent to participate in the study. * able to complete the study questionnaires. exclusion criteria: * have any of the following contraindications for treatment with nesa xsignal®: pacemakers, internal bleeding, not applying electrodes to skin in poor condition, with ulcerations or wounds, acute febrile processes, acute thrombophlebitis and/or phobia of electricity. * failure to sign the informed consent form. * active chronic inflammatory joint diseases. * active neurological diseases with central or peripheral nervous system involvement. * active systemic autoimmune diseases * psychotic disorders * active concomitant neoplastic or infectious processes * medication changes in the month prior to study inclusion or throughout the duration of the study.

Keywords: physical therapy modality pain chronic fatigue disorder sleep quality
efficacy of a self-test and self-alert mobile applet in detecting susceptible infection of covid-19

Conditions: Susceptibility to Viral and Mycobacterial Infection

Summary: the "covid-19 infection self-test and alert system" (hereinafter referred to as "covid-19 self-test applet") jointly developed by beijing tsinghua changgung hospital, institute for precision medicine, artificial intelligence of tsinghua university was launched on february 1，2020. residents , according to their actual healthy situation, after answering questions online, the system will conduct intelligent analysis, make disease risk assessment and give healthcare and medical guidance. based on the internet population survey, and referring to the diagnosis and screening standards of the national health commission of the people's republic of china, investigators carried out the mobile applet of internet survey and registry study for the internet accessible identifiable population, so as to screen the suspected population and guide the medical treatment.

the "covid-19 infection self-test and alert system" (hereinafter referred to as "covid-19 self-test applet") jointly developed by beijing tsinghua changgung hospital, institute for precision medicine, artificial intelligence of tsinghua university was launched on february 1，2020. this survey was also advocated by chinese medical doctor association. residents , or even oversea chinese people，according to their actual healthy situation, after answering questions online, the system will conduct intelligent analysis, make disease risk assessment and give healthcare and medical guidance. based on the internet population survey, and referring to the diagnosis and screening standards of the national health commission of the people's republic of china, investigators carried out the mobile applet of internet survey and registry study for the internet accessible identifiable population, so as to screen the suspected population and guide the medical treatment.

Eligibility criteria:
inclusion criteria: * people who lived in or out of china at present and threatened by the infection and spread of covid-19 * without gender and age restriction * people who have concerns of his health * voluntary completion of the self-test and evaluation. exclusion criteria: * people who are not internet accessible or can not use this mobile applet. * people who can not recognize the questionnaire.

Keywords: registry study novel coronavirus（covid-19） mobile internet survey
temporal diffusion spectroscopy mri in predicting the cps of pd-l1 expression and the efficacy of neoadjuvant therapy

Conditions: Head and Neck Squamous Cell Carcinoma; Magnetic Resonance Imaging; Neoadjuvant Therapy

Summary: the goal of this observational study is to explore the application of temporal diffusion spectroscopy mri in head and neck squamous cell carcinoma (hnscc). the main questions it aims to answer are: * if the quantitative parameters of temporal diffusion spectroscopy mri can predict the comprehensive positive score (cps) of pathological pd-l1 expression in hnscc? * if the quantitative parameters of temporal diffusion spectroscopy mri can predict the efficacy of neoadjuvant therapy in hnscc? participants will receive head and neck mri, including t2wi, t1wi, diffusion-weighted imaging (dwi), oscillating gradient spin echo (ogse) and pulsed gradient spin echo (pgse) sequence before and after neoadjuvant therapy. there is not a comparison group in our study.


Eligibility criteria:
inclusion criteria: * patients first diagnosed with head and neck squamous cell carcinoma (hnscc) by pathological biopsy * patients proposed to receive 2-3 courses of neoadjuvant chemotherapy and immunotherapy * patients without contraindications for mri, such as nonremovable ferromagnetic metal foreign body, claustrophobia, renal insufficiency, and previous history of gadolinium contrast allergy exclusion criteria: * less than 10mm in the maximum diameter of the baseline primary tumor * poor mri image quality with obvious metal or motion artifacts * the failure to complete the course of neoadjuvant therapy

Keywords: head and neck squamous cell carcinoma temporal diffusion spectroscopy imaging programmed death-ligand 1 neoadjuvant therapy
effect of flax in yogurt on blood cyanide levels

Conditions: Healthy

Summary: a randomized, controlled, cross-over post-prandial trial in healthy human volunteers will be conducted at the ih asper institute to determine the effect whole ground flaxseed, roasted then ground whole flaxseed, whole intact flaxseed and flaxseed hulls mixed into yogurt on blood cyanide levels.

participants will receive yogurt containing the following flaxseed products in a random order: 1. 40 g ground flaxseed, untreated; 2. 40 g ground flaxseed, roasted before grinding; 3. 40 g intact whole flaxseed; 4. 28 g flaxseed hulls; 5. 0 g flaxseed. venous blood will be collected at the following time points: 0 (before consumption of test product), 15, 30, 45, 60, 75, 90, 120, 150, 180 min. urine will be collected prior to consumption of test product and 180 min. primary endpoints: 1) peak blood level of cyanide and incremental area under the curve (iauc) for cyanide in blood over a 3h postprandial period. secondary endpoint: 1) cyanogenic glycoside and thiocyanate concentrations in plasma and urine over a 3h postprandial period. tertiary endpoints: 1) metabolic profile in plasma and urine over 3 h postprandial period.

Eligibility criteria:
inclusion criteria: 1. generally healthy adult, 18 years or older; 2. willing to provide informed consent; 3. willing/able to comply with the requirements of the study. exclusion criteria: 1. pregnant or lactating; 2. medical history of disease that is currently under treatment; 3. active treatment for any type of cancer within 1 year prior to study start; 4. presence of a gastrointestinal disorder, daily use of any stomach acid-lowering medications or laxatives (including fibre supplements) within the past month or antibiotic use within the past 6 weeks; 5. plasma concentration of vitamin b12 \< 148 pmol/l; 6. complete blood count outside normal range; 7. medical history of liver disease or liver dysfunction (defined as plasma ast or alt ≥3 times the upper limit of normal (uln)); 8. fasting blood glucose ≥6.1 mmol/l and/or hba1c ≥6.0%; 9. fasting plasma total cholesterol \>7.8 mmol/l; 10. fasting plasma hdl \<0.9 mmol/l; 11. fasting plasma ldl \>5.0 mmol/l; 12. fasting plasma triglycerides \>2.3 mmol/l; 13. systolic blood pressure \>140 mmhg or diastolic blood pressure \>90 mmhg; 14. major surgery within the last 3 months; 15. smoking, use of tobacco, vape or cannabis (within the last week); 16. allergies to flaxseed or yogurt; 17. aversion or unwillingness to eat study foods; 18. participation in another clinical trial, current or in the past 4 weeks

Keywords: flax blood cyanide
the french esogastrictumours data base

Conditions: Esophageal Disease

Summary: this retrospective study aims at evaluating the outcomes of gastrointestinal stromal tumor after surgery.


Eligibility criteria:
inclusion criteria: patient with * esophageal cancer, gastric or gastroesophageal junction diagnosed biopsy , regardless of the subtype of cancer, tumor stage or treatment envisaged. * naive treatment for this cancer, * naive treatment for this cancer , failing that received neoadjuvant treatment , * male or female ≥ 18 years. * social protection scheme . * sign a free and informed consent for blood sampling , the different questionnaires and the collection of patient information. exclusion criteria: male or female aged ( e) under 18 years. * private person of liberty or under supervision (including guardianship ) . * people who do not speak french. * major nobody unable to consent . * patient fregat already included in the base. * patient refusal .

Keywords: esophagus surgery
perioperative medical program to optimize nerve regeneration after robot-assisted laparoscopic neurolyses of pudendal and/or inferior cluneal nerves for chronic neuralgias: results after 1-year follow-up

Conditions: Pudendal Neuralgia; Neuralgia

Summary: pudendal and inferior cluneal neuralgias are responsible for chronic pelvicperineal pain. these two neuralgias are associated in approximately 25% of cases. in the event of failure of first-line multimodal medical treatment, a mini-invasive robot-assisted laparoscopic decompression can be proposed. these surgeries carry the risk of neurapraxia, leading to a temporary increase in neuropathic pain and numbness in the nerve sensitive area, a motoric or neurovegetative disturbance (pudendal).


Eligibility criteria:
inclusion criteria: * patients over 18 years old * patients presenting a pudendal and/or inferior cluneal neuralgias with failure of the medical treatment * patient having given consent after reading the information note exclusion criteria: * inoperable patients (contraindications to anesthesia or surgery) surgical contraindications) * person deprived of liberty or under guardianship * person under court protection * pregnant or breast-feeding woman * minors
surgical treatment for trapeziometacarpal osteoarthritis eaton & glickel stage 4

Conditions: Trapeziometacarpal Osteoarthritis; Thumb Carpometacarpal Osteoarthritis

Summary: trapeziometacarpal osteoarthritis is a common cause of pain and loss of hand function in postmenopausal women. many surgical treatments have been described and recent literature has show that the relatively simple trapeziectomy gives equal results and less complications, when compared to other techniques such as ligament reconstructions and interpositions. these studies have been conducted predominantly in patients with stage 2 or 3 osteoarthritis. stage 4 osteoarthritis is characterized by more cartilage and soft-tissue damage, which increases the chance for collapse of the first metacarpal bone and associated problems. the investigators' hypothesis is that an lrti can be of additional value in patients with stage 4 osteoarthritis.


Eligibility criteria:
inclusion criteria: * women * 40 years of age or more * symptomatic trapeziometacarpal osteoarthritis * eaton \& glickel stage 4 exclusion criteria: * an operation for trapeziometacarpal osteoarthritis on the same hand in the past. * participation in randomized clinical trial for trapeziometacarpal osteoarthritis with contralateral hand. * secondary trapeziometacarpal osteoarthritis as result of trauma, rheumatoid arthritis, systemic lupus or gout. * symptomatic carpal tunnel syndrome in same hand. * symptomatic quervain's tenosynovitis in same hand. * neurological or other disorders of the affected side that can influence postoperative rehabilitation. * insufficient knowledge of dutch language.

Keywords: osteoarthritis thumb lrti trapeziectomy
effectiveness of a case management model for patients with hypertension and type ii diabetes in chile

Conditions: Hypertension; Diabetes Mellitus, Type 2

Summary: the purpose of this study is to evaluate whether a new model of health care for chronic patients, based on case management and guided by a nurse which targets the patient´s risk, is more effective than usual care at primary health care in chile. additionally, this intervention would provide a better quality of care and a more efficient health provision.


Eligibility criteria:
inclusion criteria: * adults diagnosed with hypertension and/ or type 2 diabetes exclusion criteria: * severe mental illness and / or deterioration of cognitive abilities. * severe hearing loss. * diagnosed with cancer * stage 4 or 5 of chronic kidney disease

Keywords: hypertension diabetes mellitus, type 2 case management
molecular determinants affecting fluoro-l-thymidine (flt) positron emission tomography (pet) in rectal cancer

Conditions: Rectal Cancer

Summary: the purpose of this study is to determine if positron emission tomography (pet) imaging with an imaging agent called 18f-fluorodeoxythymidine(\[18f\]-flt) will allow investigators to measure how well tumor(s) respond to treatment without taking a tissue sample (biopsy). additionally, the investigators want to determine if it is possible to predict how well tumor(s) might respond to treatment with \[18f\]-flt pet imaging.


Eligibility criteria:
inclusion criteria: * subjects with known rectal cancer. * subjects must have signed an approved consent form. * subjects must be 18 years of age or older. exclusion criteria: * children less than 18 are excluded. * pregnant women and women who are breast feeding will be excluded from this study. a serum beta hcg will also be performed for each pre-menopausal female subject. * patients who are acutely ill who are deemed by their treating physician as not suitable candidates for this study
tight glycemic control by artificial pancreas

Conditions: Pancreatic Neoplasm

Summary: this study evaluated a closed-loop system providing continuous monitoring and strict control of perioperative blood glucose following pancreatic resection.

this study recruited 32 patients undergoing elective pancreatic resection for pancreatic disease.

Eligibility criteria:
inclusion criteria: * this study recruited 32 patients undergoing elective pancreatic resection for pancreatic disease. exclusion criteria: * weight loss greater than 10% during the previous 6 months * signs of distant metastasis * respiratory, renal,or heart disease * patients provided written informed consent prior to enrollment

Keywords: pancreatogenic diabetes artificial pancreas
evaluation of the macular, peripapillary nerve fiber layer and choroid thickness changes in the gestational diabetes mellitus, healthy pregnant and women volunteers.

Conditions: Retinal Evaluation in Patients With GDM.

Summary: gestational diabetes mellitus (gdm) is a risk factor for the development of type ii diabetes and it is responsible for the morbidity of both mother and child. the aim of this study was to determine retinal findings of gestational diabetes mellitus (gdm).

we have three groups; the first group consisted of pregnant volunteers with gdm. the second group consisted of healthy pregnant participants. the third group consisted of healthy, non-pregnant women at the reproductive age. macular, choroid and retinal nerve fiber layer (rnfl) thicknesses were evaluated in patients with gdm and comparisons were made among gdm, healthy pregnant and healthy non-pregnant subjects for these parameters by using optic cohorence tomography.

Eligibility criteria:
inclusion criteria: singleton pregnancies pregnancies between 26-28 weeks of gestation gestational diabetes exclusion criteria: * ocular surgery ocular trauma glaucoma cystoid macular edema macular degeneration optic atrophy

Keywords: gestational diabetes mellitus; optical coherence tomography; pregnancy; retinal nerve fiber layer.
continuing care and treatment for patients with cancer/aids/skin disease

Conditions: Cancer; HIV

Summary: this protocol is to provide continuing medical/surgical/radio-therapeutic care, treatment and follow-up for nci patients not currently entered on an active research protocol. no investigational treatments will be administered on this protocol.

background: it may be in the interest of the ccr to continue to follow and treat certain subjects after they have completed their treatment and participation on a research protocol. objective: to provide continuing treatment and medical follow-up for ccr subjects who have completed their treatment and participation on a research protocol and who are not currently entered on or eligible for another active research protocol. eligibility: subjects who have been previously enrolled on and received treatment according to an approved ccr research protocol. (clinical trial) it is in the best interest of the subject and the ccr for the subject to continue to receive standard care and follow-up at the nih. design: medical/surgical/radiotherapeutic care, treatment and follow-up is provided for ccr subjects who have completed their treatment and participation on a research protocol and who are not currently entered on an active research protocol. no investigational treatments will be administered. this protocol is not be used as a platform to perform pilot studies of off-label uses for standard agents.

Eligibility criteria:
* inclusion criteria: subjects of any age who have been previously enrolled and treated on an approved ccr research treatment protocol. it is in the best interests of the subject and the ccr for the subject to continue to receive treatment and follow-up at the nih. the subject or guardian signs the informed consent and agrees to the proposed treatment regimen. exclusion criteria: subjects who have not been previously treated on a ccr research treatment protocol. subjects who are receiving an investigational therapy.

Keywords: follow-up treatment